▶ 調査レポート

世界の細胞株生成市場 2028年:過剰発現安定細胞株、Shrnaノックダウン安定細胞株、Tet誘導性遺伝子発現安定細胞株、Crispr安定細胞株

• 英文タイトル:Global Cell Line Generation Market Insights, Forecast to 2028

Global Cell Line Generation Market Insights, Forecast to 2028「世界の細胞株生成市場 2028年:過剰発現安定細胞株、Shrnaノックダウン安定細胞株、Tet誘導性遺伝子発現安定細胞株、Crispr安定細胞株」(市場規模、市場予測)調査レポートです。• レポートコード:QY2207C3472
• 出版社/出版日:QYResearch / 2022年7月11日
• レポート形態:英文、PDF、116ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Multi User¥1,087,800 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界の細胞株生成の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に細胞株生成の世界市場のxxx%を占める「過剰発現安定細胞株」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「医療産業」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国の細胞株生成の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの細胞株生成市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの細胞株生成市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

細胞株生成のグローバル主要メーカーには、Merck KGaA、VectorBuilder、Thermo Fisher Scientific、Creative Biogene、Molecular Devices, LLC、Esco Aster Pte、ALSTEM, Inc.、Creative BioMart、Altogen Labs、SB Drug Discovery、BPS Bioscience, Inc.、ProteoGenix、Biologics International Corp (BIC)、Advanced Instruments、Sphere Fluidics Limitedなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

細胞株生成市場は、種類と用途によって区分されます。世界の細胞株生成市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
過剰発現安定細胞株、Shrnaノックダウン安定細胞株、Tet誘導性遺伝子発現安定細胞株、Crispr安定細胞株

【用途別セグメント】
医療産業、生物産業、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 細胞株生成製品概要
- 種類別市場(過剰発現安定細胞株、Shrnaノックダウン安定細胞株、Tet誘導性遺伝子発現安定細胞株、Crispr安定細胞株)
- 用途別市場(医療産業、生物産業、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の細胞株生成販売量予測2017-2028
- 世界の細胞株生成売上予測2017-2028
- 細胞株生成の地域別販売量
- 細胞株生成の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別細胞株生成販売量
- 主要メーカー別細胞株生成売上
- 主要メーカー別細胞株生成価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(過剰発現安定細胞株、Shrnaノックダウン安定細胞株、Tet誘導性遺伝子発現安定細胞株、Crispr安定細胞株)
- 細胞株生成の種類別販売量
- 細胞株生成の種類別売上
- 細胞株生成の種類別価格
・用途別市場規模(医療産業、生物産業、その他)
- 細胞株生成の用途別販売量
- 細胞株生成の用途別売上
- 細胞株生成の用途別価格
・北米市場
- 北米の細胞株生成市場規模(種類別、用途別)
- 主要国別の細胞株生成市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの細胞株生成市場規模(種類別、用途別)
- 主要国別の細胞株生成市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の細胞株生成市場規模(種類別、用途別)
- 主要国別の細胞株生成市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の細胞株生成市場規模(種類別、用途別)
- 主要国別の細胞株生成市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの細胞株生成市場規模(種類別、用途別)
- 主要国別の細胞株生成市場規模(トルコ、サウジアラビア)
・企業情報
Merck KGaA、VectorBuilder、Thermo Fisher Scientific、Creative Biogene、Molecular Devices, LLC、Esco Aster Pte、ALSTEM, Inc.、Creative BioMart、Altogen Labs、SB Drug Discovery、BPS Bioscience, Inc.、ProteoGenix、Biologics International Corp (BIC)、Advanced Instruments、Sphere Fluidics Limited
・産業チェーン及び販売チャネル分析
- 細胞株生成の産業チェーン分析
- 細胞株生成の原材料
- 細胞株生成の生産プロセス
- 細胞株生成の販売及びマーケティング
- 細胞株生成の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 細胞株生成の産業動向
- 細胞株生成のマーケットドライバー
- 細胞株生成の課題
- 細胞株生成の阻害要因
・主な調査結果

Market Analysis and Insights: Global Cell Line Generation Market
The global Cell Line Generation market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Overexpression Stable Cell Lines accounting for % of the Cell Line Generation global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Medical Industry segment is altered to an % CAGR throughout this forecast period.
China Cell Line Generation market size is valued at US$ million in 2021, while the North America and Europe Cell Line Generation are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cell Line Generation landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cell Line Generation market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cell Line Generation market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cell Line Generation market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cell Line Generation market.
Global Cell Line Generation Scope and Market Size
Cell Line Generation market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Cell Line Generation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Overexpression Stable Cell Lines
Shrna Knockdown Stable Cell Lines
Tet Inducible Gene Expression Stable Cell Lines
Crispr Stable Cell Lines
Segment by Application
Medical Industry
Biological Industry
Others
By Company
Merck KGaA
VectorBuilder
Thermo Fisher Scientific
Creative Biogene
Molecular Devices, LLC
Esco Aster Pte
ALSTEM, Inc.
Creative BioMart
Altogen Labs
SB Drug Discovery
BPS Bioscience, Inc.
ProteoGenix
Biologics International Corp (BIC)
Advanced Instruments
Sphere Fluidics Limited
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell Line Generation Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Overexpression Stable Cell Lines
1.2.3 Shrna Knockdown Stable Cell Lines
1.2.4 Tet Inducible Gene Expression Stable Cell Lines
1.2.5 Crispr Stable Cell Lines
1.3 Market by Application
1.3.1 Global Cell Line Generation Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Medical Industry
1.3.3 Biological Industry
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cell Line Generation Market Perspective (2017-2028)
2.2 Cell Line Generation Growth Trends by Region
2.2.1 Cell Line Generation Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Cell Line Generation Historic Market Size by Region (2017-2022)
2.2.3 Cell Line Generation Forecasted Market Size by Region (2023-2028)
2.3 Cell Line Generation Market Dynamics
2.3.1 Cell Line Generation Industry Trends
2.3.2 Cell Line Generation Market Drivers
2.3.3 Cell Line Generation Market Challenges
2.3.4 Cell Line Generation Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell Line Generation Players by Revenue
3.1.1 Global Top Cell Line Generation Players by Revenue (2017-2022)
3.1.2 Global Cell Line Generation Revenue Market Share by Players (2017-2022)
3.2 Global Cell Line Generation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell Line Generation Revenue
3.4 Global Cell Line Generation Market Concentration Ratio
3.4.1 Global Cell Line Generation Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell Line Generation Revenue in 2021
3.5 Cell Line Generation Key Players Head office and Area Served
3.6 Key Players Cell Line Generation Product Solution and Service
3.7 Date of Enter into Cell Line Generation Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell Line Generation Breakdown Data by Type
4.1 Global Cell Line Generation Historic Market Size by Type (2017-2022)
4.2 Global Cell Line Generation Forecasted Market Size by Type (2023-2028)
5 Cell Line Generation Breakdown Data by Application
5.1 Global Cell Line Generation Historic Market Size by Application (2017-2022)
5.2 Global Cell Line Generation Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Cell Line Generation Market Size (2017-2028)
6.2 North America Cell Line Generation Market Size by Type
6.2.1 North America Cell Line Generation Market Size by Type (2017-2022)
6.2.2 North America Cell Line Generation Market Size by Type (2023-2028)
6.2.3 North America Cell Line Generation Market Share by Type (2017-2028)
6.3 North America Cell Line Generation Market Size by Application
6.3.1 North America Cell Line Generation Market Size by Application (2017-2022)
6.3.2 North America Cell Line Generation Market Size by Application (2023-2028)
6.3.3 North America Cell Line Generation Market Share by Application (2017-2028)
6.4 North America Cell Line Generation Market Size by Country
6.4.1 North America Cell Line Generation Market Size by Country (2017-2022)
6.4.2 North America Cell Line Generation Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Cell Line Generation Market Size (2017-2028)
7.2 Europe Cell Line Generation Market Size by Type
7.2.1 Europe Cell Line Generation Market Size by Type (2017-2022)
7.2.2 Europe Cell Line Generation Market Size by Type (2023-2028)
7.2.3 Europe Cell Line Generation Market Share by Type (2017-2028)
7.3 Europe Cell Line Generation Market Size by Application
7.3.1 Europe Cell Line Generation Market Size by Application (2017-2022)
7.3.2 Europe Cell Line Generation Market Size by Application (2023-2028)
7.3.3 Europe Cell Line Generation Market Share by Application (2017-2028)
7.4 Europe Cell Line Generation Market Size by Country
7.4.1 Europe Cell Line Generation Market Size by Country (2017-2022)
7.4.2 Europe Cell Line Generation Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell Line Generation Market Size (2017-2028)
8.2 Asia-Pacific Cell Line Generation Market Size by Type
8.2.1 Asia-Pacific Cell Line Generation Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Cell Line Generation Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Cell Line Generation Market Share by Type (2017-2028)
8.3 Asia-Pacific Cell Line Generation Market Size by Application
8.3.1 Asia-Pacific Cell Line Generation Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Cell Line Generation Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Cell Line Generation Market Share by Application (2017-2028)
8.4 Asia-Pacific Cell Line Generation Market Size by Region
8.4.1 Asia-Pacific Cell Line Generation Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Cell Line Generation Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Cell Line Generation Market Size (2017-2028)
9.2 Latin America Cell Line Generation Market Size by Type
9.2.1 Latin America Cell Line Generation Market Size by Type (2017-2022)
9.2.2 Latin America Cell Line Generation Market Size by Type (2023-2028)
9.2.3 Latin America Cell Line Generation Market Share by Type (2017-2028)
9.3 Latin America Cell Line Generation Market Size by Application
9.3.1 Latin America Cell Line Generation Market Size by Application (2017-2022)
9.3.2 Latin America Cell Line Generation Market Size by Application (2023-2028)
9.3.3 Latin America Cell Line Generation Market Share by Application (2017-2028)
9.4 Latin America Cell Line Generation Market Size by Country
9.4.1 Latin America Cell Line Generation Market Size by Country (2017-2022)
9.4.2 Latin America Cell Line Generation Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell Line Generation Market Size (2017-2028)
10.2 Middle East & Africa Cell Line Generation Market Size by Type
10.2.1 Middle East & Africa Cell Line Generation Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Cell Line Generation Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Cell Line Generation Market Share by Type (2017-2028)
10.3 Middle East & Africa Cell Line Generation Market Size by Application
10.3.1 Middle East & Africa Cell Line Generation Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Cell Line Generation Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Cell Line Generation Market Share by Application (2017-2028)
10.4 Middle East & Africa Cell Line Generation Market Size by Country
10.4.1 Middle East & Africa Cell Line Generation Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Cell Line Generation Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck KGaA
11.1.1 Merck KGaA Company Details
11.1.2 Merck KGaA Business Overview
11.1.3 Merck KGaA Cell Line Generation Introduction
11.1.4 Merck KGaA Revenue in Cell Line Generation Business (2017-2022)
11.1.5 Merck KGaA Recent Developments
11.2 VectorBuilder
11.2.1 VectorBuilder Company Details
11.2.2 VectorBuilder Business Overview
11.2.3 VectorBuilder Cell Line Generation Introduction
11.2.4 VectorBuilder Revenue in Cell Line Generation Business (2017-2022)
11.2.5 VectorBuilder Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Details
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Cell Line Generation Introduction
11.3.4 Thermo Fisher Scientific Revenue in Cell Line Generation Business (2017-2022)
11.3.5 Thermo Fisher Scientific Recent Developments
11.4 Creative Biogene
11.4.1 Creative Biogene Company Details
11.4.2 Creative Biogene Business Overview
11.4.3 Creative Biogene Cell Line Generation Introduction
11.4.4 Creative Biogene Revenue in Cell Line Generation Business (2017-2022)
11.4.5 Creative Biogene Recent Developments
11.5 Molecular Devices, LLC
11.5.1 Molecular Devices, LLC Company Details
11.5.2 Molecular Devices, LLC Business Overview
11.5.3 Molecular Devices, LLC Cell Line Generation Introduction
11.5.4 Molecular Devices, LLC Revenue in Cell Line Generation Business (2017-2022)
11.5.5 Molecular Devices, LLC Recent Developments
11.6 Esco Aster Pte
11.6.1 Esco Aster Pte Company Details
11.6.2 Esco Aster Pte Business Overview
11.6.3 Esco Aster Pte Cell Line Generation Introduction
11.6.4 Esco Aster Pte Revenue in Cell Line Generation Business (2017-2022)
11.6.5 Esco Aster Pte Recent Developments
11.7 ALSTEM, Inc.
11.7.1 ALSTEM, Inc. Company Details
11.7.2 ALSTEM, Inc. Business Overview
11.7.3 ALSTEM, Inc. Cell Line Generation Introduction
11.7.4 ALSTEM, Inc. Revenue in Cell Line Generation Business (2017-2022)
11.7.5 ALSTEM, Inc. Recent Developments
11.8 Creative BioMart
11.8.1 Creative BioMart Company Details
11.8.2 Creative BioMart Business Overview
11.8.3 Creative BioMart Cell Line Generation Introduction
11.8.4 Creative BioMart Revenue in Cell Line Generation Business (2017-2022)
11.8.5 Creative BioMart Recent Developments
11.9 Altogen Labs
11.9.1 Altogen Labs Company Details
11.9.2 Altogen Labs Business Overview
11.9.3 Altogen Labs Cell Line Generation Introduction
11.9.4 Altogen Labs Revenue in Cell Line Generation Business (2017-2022)
11.9.5 Altogen Labs Recent Developments
11.10 SB Drug Discovery
11.10.1 SB Drug Discovery Company Details
11.10.2 SB Drug Discovery Business Overview
11.10.3 SB Drug Discovery Cell Line Generation Introduction
11.10.4 SB Drug Discovery Revenue in Cell Line Generation Business (2017-2022)
11.10.5 SB Drug Discovery Recent Developments
11.11 BPS Bioscience, Inc.
11.11.1 BPS Bioscience, Inc. Company Details
11.11.2 BPS Bioscience, Inc. Business Overview
11.11.3 BPS Bioscience, Inc. Cell Line Generation Introduction
11.11.4 BPS Bioscience, Inc. Revenue in Cell Line Generation Business (2017-2022)
11.11.5 BPS Bioscience, Inc. Recent Developments
11.12 ProteoGenix
11.12.1 ProteoGenix Company Details
11.12.2 ProteoGenix Business Overview
11.12.3 ProteoGenix Cell Line Generation Introduction
11.12.4 ProteoGenix Revenue in Cell Line Generation Business (2017-2022)
11.12.5 ProteoGenix Recent Developments
11.13 Biologics International Corp (BIC)
11.13.1 Biologics International Corp (BIC) Company Details
11.13.2 Biologics International Corp (BIC) Business Overview
11.13.3 Biologics International Corp (BIC) Cell Line Generation Introduction
11.13.4 Biologics International Corp (BIC) Revenue in Cell Line Generation Business (2017-2022)
11.13.5 Biologics International Corp (BIC) Recent Developments
11.14 Advanced Instruments
11.14.1 Advanced Instruments Company Details
11.14.2 Advanced Instruments Business Overview
11.14.3 Advanced Instruments Cell Line Generation Introduction
11.14.4 Advanced Instruments Revenue in Cell Line Generation Business (2017-2022)
11.14.5 Advanced Instruments Recent Developments
11.15 Sphere Fluidics Limited
11.15.1 Sphere Fluidics Limited Company Details
11.15.2 Sphere Fluidics Limited Business Overview
11.15.3 Sphere Fluidics Limited Cell Line Generation Introduction
11.15.4 Sphere Fluidics Limited Revenue in Cell Line Generation Business (2017-2022)
11.15.5 Sphere Fluidics Limited Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer